Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$143.49 USD

143.49
736,466

+3.55 (2.54%)

Updated Oct 9, 2024 04:00 PM ET

After-Market: $143.53 +0.04 (0.03%) 6:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Hill-Rom's Buyout of Voalte to Bolster Digital Connectivity

by Zacks Equity Research

Hill-Rom (HRC) anticipates Voalte acquisition to be modestly dilutive to its adjusted EPS in fiscal 2019.

GNC Holdings Global Business Strong, Domestic Sales Weak

by Zacks Equity Research

Within same store, GNC Holdings (GNC) performs dismally at domestic franchise locations.

Tandem Diabetes Signs as an Insulin Pump Vendor in Canada

by Zacks Equity Research

Tandem Diabetes' (TNDM) insulin pump seems to be a strategic fit and well-timed from its massive uptake by the diabetic patients in Canada.

Invitae (NVTA) Scales a New 52-Week High on Solid Prospects

by Zacks Equity Research

One of the key growth drivers for Invitae (NVTA) is an increase in billable tests over the past year.

ResMed's New Brightree Suite to Boost Home Infusion Business

by Zacks Equity Research

ResMed's (RMD) Brightree suite upgrade will help uplift business operations by easily meeting compliance needs and offering the best quality patient care.

    Resmed (RMD) to Acquire HB Healthcare to Treat Sleep Apnea

    by Zacks Equity Research

    ResMed (RMD) to expand in CPAP and respiratory care market in Korea.

    Cooper Companies (COO) Hits 52-Week High on Solid Prospects

    by Zacks Equity Research

    Cooper Companies' (COO) revenues across CooperVision and CooperSurgery see growth.

    Walgreens Boots Rides on Retail Pharmacy USA, Strategic Deals

    by Zacks Equity Research

    Walgreens Boots' (WBA) Retail Pharmacy USA division benefits from comparable prescription growth and a strong retail prescription market.

    Henry Schien Buys North American Rescue, Expands Medical Arm

    by Zacks Equity Research

    Henry Schien (HSIC) believes that acquisition of NAR's business will offer multiple growth opportunities and promising business synergies.

    Medtronic's Mazor Robotics Aid Growth, Rising Costs Ail

    by Zacks Equity Research

    We are upbeat about the recently-concluded buyout of Mazor Robotics, which is likely to solidify Medtronic's (MDT) position in the spine surgery space.

    Medtronic Launches Grafton DBM Bone Grafting Product in Japan

    by Zacks Equity Research

    Grafton DBM to strengthen Medtronic's (MDT) foothold in Japan.

    Medtronic Gets FDA Approval for Accurian RF Ablation Platform

    by Zacks Equity Research

    Medtronic's (MDT) RF ablation platform will use radio waves to provide relief from chronic pain.

    Integra Rides on Channel Expansion Strategy, New Alliances

    by Zacks Equity Research

    Integra's (IART) success with its channel expansion strategy and Codman integration buoys investors' optimism on the stock.

    ResMed Inks Deal With PharMerica on Medication Management

    by Zacks Equity Research

    The deal between ResMed's (RMD) MatrixCare and PharMerica covers NCPDP (National Council for Prescription Drug Programs) Bidirectional ePrescribing with all MatrixCare customer facilities.

    DexCom (DXCM) Gets Health Canada Approval for G6 CGM System

    by Zacks Equity Research

    DexCom's (DXCM) G6 CGM system intends to serve diabetes patients of all age groups in Canada.

    Masimo (MASI) Q4 Earnings and Revenues Beat, Guidance Solid

    by Zacks Equity Research

    Masimo (MASI) sees an increase in shipments of noninvasive technology in Q4.

    Masimo and Saudi Arabia MOH Collaborate for CCHD Screening

    by Zacks Equity Research

    Studies have shown that Masimo's (MASI) SET pulse oximetry can improve CCHD screening, helping to save newborns.

    Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings?

    by Zacks Equity Research

    Focus on cloud-based services is likely to boost Veeva Systems' (VEEV) fiscal Q4 results.

    What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?

    by Zacks Equity Research

    Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.

    HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?

    by Zacks Equity Research

    HMS Holdings (HMSY) expects to gain from its total population management or TPM business in fourth-quarter 2018.

    What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?

    by Zacks Equity Research

    Genomic Health (GHDX) is expected to gain from higher Oncotype DX breast cancer test revenues in Q4.

    Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?

    by Zacks Equity Research

    Henry Schein (HSIC) is well placed to gain from digitalization in the global dental market.

    Here's What Will Give Shape to Medtronic's (MDT) Q3 Earnings

    by Zacks Equity Research

    Medtronic (MDT) is expected to maintain a decent market share in the core pacing backed by the continued uptake of Micra Transcatheter Pacing System in Q3.

    DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.

    What's in the Offing for DaVita (DVA) This Earnings Season?

    by Zacks Equity Research

    DaVita (DVA) expects headwinds in DaVita Rx, while overseas prospects of the dialysis business look bright.